ThromboGenics granted 6-month review for eye treatment
04:20 EDT 4 Jul 2012 | SCRIP
ThromboGenics officially revealed that the US FDA has accepted for review the firm's biologics license application (BLA) for ocriplasmin intravitreal as a treatment for symptomatic vitreomacular adhesion (VMA), including macular hole, a progressive..
Original Article: ThromboGenics granted 6-month review for eye treatment
More From BioPortfolio on "ThromboGenics granted 6-month review for eye treatment"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
